Methods and compositions for the treatment of cancer or other diseases
The present invention relates to methods and compositions for the treatment of diseases, including cancer, infectious diseases and autoimmune diseases. The present invention also relates to methods and compositions for improving immune function. More particularly, the present invention relates to multifunctional molecules that are capable of being delivered to cells of interest for the treatment of diseases and for the improvement in immune function.
1. An oligonucleotide comprising a modified human STAT3 sense strand comprising an oligonucleotide having the nucleotides set forth in SEQ ID NO:17, wherein nucleotides at positions 3, 4, 7, 9, 10, 12-4, 16-19 and 23 are modified and wherein the modifications are independently selected from the group consisting of a 2′-alkyl pyrimidine, 2′F, 2′OMe, amino, a deoxynucleotide, an abasic sugar, a 2-O-alkyl modified pyrimidine, 4-thiouracil, 5-bromouracil, 5-iodouracil, 5-(3-aminoallyl)-uracil and LNA.
2. A chimeric molecule comprising a modified human STAT3 sense strand and a human CpG(D19)-STAT3 antisense strand, wherein the modified human STAT3 sense strand is the oligonucleotide of claim 1 , wherein the human CpG(D19)-STAT3 antisense strand comprises (a) a first oligonucleotide having the nucleotides set forth in SEQ ID NO:16, (b) a C3 carbon chain or propanediol linker and (c) a second oligonucleotide having the nucleotides set forth in SEQ ID NO:5 that is the antisense strand, and wherein the sense strand and the antisense strand anneal to form a double stranded siRNA.
3. A chimeric molecule comprising a human STAT3 sense strand-overhang, a human CpG(D19)-overhang and a human STAT3 antisense strand, wherein the human STAT3 sense strand-overhang comprises (a) an oligonucleotide having the nucleotides set forth in SEQ ID NO:18 that is the sense strand, (b) a C3 carbon chain or propanediol linker and (c) an oligonucleotide having the nucleotides set forth in SEQ ID NO:19 that is the overhang, wherein nucleotides at positions 2, 4, 7, 8 and 11-15 of SEQ ID NO:19 are modified, wherein the human CpG(D19)-overhang comprises (a) an oligonucleotide having the nucleotides set forth in SEQ ID NO:16, (b) a C3 carbon chain or propanediol linker and (c) an oligonucleotide having the nucleotides set forth in SEQ ID NO:20 that is the overhang, wherein nucleotides at positions 7, 8, 11, 12, 14 and 15 of SEQ ID NO:20 are modified, wherein the human STAT3 antisense strand comprises an oligonucleotide having the nucleotides set forth in SEQ ID NO:5, wherein the modifications are independently selected from the group consisting of a 2′-alkyl pyrimidine, 2′F, 2′OMe, amino, a deoxynucleotide, an abasic sugar, a 2-O-alkyl modified pyrimidine, 4-thiouracil, 5-bromouracil, 5-iodouracil, 5-(3-aminoallyl)-uracil and LNA, wherein the overhangs anneal to form a double stranded RNA, and wherein the sense strand and the antisense strand anneal to form a double stranded siRNA.